Key Points
- Insider sale: CAO Maricel Apuli sold 2,000 shares on Dec. 8 at an average price of $74.26 for $148,520, leaving her with 130,297 shares (a 1.51% reduction in her position).
- Recent results and stock level: BridgeBio reported Q earnings of ($0.95) EPS (missing estimates) but beat revenue at $120.7M (up 4,318% YoY), and the stock is trading near its 52‑week high (~$74) with a $14.26B market cap.
- Analyst sentiment: The consensus is a "Moderate Buy" (21 Buys, 1 Sell) with a consensus price target of $75.35, while several firms have raised targets (e.g., Cantor Fitzgerald to $110, UBS to $82).
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction on Monday, December 8th. The stock was sold at an average price of $74.26, for a total value of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares of the company's stock, valued at $9,675,855.22. The trade was a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
BridgeBio Pharma Stock Performance
NASDAQ BBIO opened at $74.00 on Thursday. The business's fifty day moving average is $63.23 and its 200 day moving average is $52.10. The company has a market capitalization of $14.26 billion, a PE ratio of -17.69 and a beta of 1.26. BridgeBio Pharma, Inc. has a fifty-two week low of $25.34 and a fifty-two week high of $75.10.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The firm had revenue of $120.70 million during the quarter, compared to analysts' expectations of $107.71 million. During the same quarter in the prior year, the business earned ($0.86) earnings per share. The firm's revenue for the quarter was up 4318.0% on a year-over-year basis. On average, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have weighed in on BBIO. UBS Group lifted their price target on shares of BridgeBio Pharma from $72.00 to $82.00 and gave the company a "buy" rating in a report on Friday, September 12th. Cantor Fitzgerald lifted their target price on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Thursday, October 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of BridgeBio Pharma in a report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of BridgeBio Pharma in a research note on Monday, November 3rd. Finally, Truist Financial reissued a "buy" rating and set a $80.00 target price (up previously from $66.00) on shares of BridgeBio Pharma in a research note on Thursday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, BridgeBio Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $75.35.
Get Our Latest Report on BBIO
Institutional Investors Weigh In On BridgeBio Pharma
Several large investors have recently bought and sold shares of BBIO. Swiss Life Asset Management Ltd purchased a new stake in BridgeBio Pharma during the third quarter valued at $346,000. CIBC Private Wealth Group LLC increased its holdings in shares of BridgeBio Pharma by 384.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 7,759 shares of the company's stock worth $403,000 after buying an additional 6,156 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at about $866,000. Danske Bank A S purchased a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at about $104,000. Finally, Castleark Management LLC lifted its holdings in shares of BridgeBio Pharma by 58.9% in the 3rd quarter. Castleark Management LLC now owns 123,707 shares of the company's stock valued at $6,425,000 after acquiring an additional 45,867 shares during the last quarter. Institutional investors own 99.85% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
